ATE424847T1 - Kombinationen aus antimuscarinischen mitteln und beta-adrenergen agonisten - Google Patents

Kombinationen aus antimuscarinischen mitteln und beta-adrenergen agonisten

Info

Publication number
ATE424847T1
ATE424847T1 AT05750538T AT05750538T ATE424847T1 AT E424847 T1 ATE424847 T1 AT E424847T1 AT 05750538 T AT05750538 T AT 05750538T AT 05750538 T AT05750538 T AT 05750538T AT E424847 T1 ATE424847 T1 AT E424847T1
Authority
AT
Austria
Prior art keywords
antimuscarinoic
beta
agents
combinations
adrenergic agonists
Prior art date
Application number
AT05750538T
Other languages
German (de)
English (en)
Inventor
Escardo Jordi Gras
Calvo Jesus Llenas
Hamish Ryder
Diaz Pio Orviz
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424847(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Application granted granted Critical
Publication of ATE424847T1 publication Critical patent/ATE424847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Wrappers (AREA)
AT05750538T 2004-05-31 2005-05-31 Kombinationen aus antimuscarinischen mitteln und beta-adrenergen agonisten ATE424847T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Publications (1)

Publication Number Publication Date
ATE424847T1 true ATE424847T1 (de) 2009-03-15

Family

ID=34956036

Family Applications (3)

Application Number Title Priority Date Filing Date
AT05750538T ATE424847T1 (de) 2004-05-31 2005-05-31 Kombinationen aus antimuscarinischen mitteln und beta-adrenergen agonisten
AT07019644T ATE474600T1 (de) 2004-05-31 2005-05-31 Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
AT05751702T ATE417627T1 (de) 2004-05-31 2005-05-31 Kombinationen aus antimuscarinischen mitteln und corticosteroiden

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT07019644T ATE474600T1 (de) 2004-05-31 2005-05-31 Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
AT05751702T ATE417627T1 (de) 2004-05-31 2005-05-31 Kombinationen aus antimuscarinischen mitteln und corticosteroiden

Country Status (45)

Country Link
US (41) US20050288266A1 (enExample)
EP (14) EP2138188A1 (enExample)
JP (8) JP5133054B2 (enExample)
KR (3) KR20130027586A (enExample)
CN (8) CN102755321B (enExample)
AR (1) AR049066A1 (enExample)
AT (3) ATE424847T1 (enExample)
AU (3) AU2005247107B2 (enExample)
BE (1) BE1016608A5 (enExample)
BR (6) BRPI0511666A (enExample)
CA (3) CA2568566C (enExample)
CH (1) CH696962A5 (enExample)
CL (1) CL2011000607A1 (enExample)
CY (7) CY1108885T1 (enExample)
DE (3) DE602005011803D1 (enExample)
DK (5) DK1891973T3 (enExample)
EC (6) ECSP067035A (enExample)
ES (7) ES2257152B1 (enExample)
FR (2) FR2870744B1 (enExample)
GB (1) GB2419819B (enExample)
GR (1) GR1006045B (enExample)
HR (4) HRP20090215T4 (enExample)
HU (2) HUP0600139A3 (enExample)
IL (3) IL179689A (enExample)
IT (1) ITMI20051021A1 (enExample)
LT (1) LTC1763368I2 (enExample)
LU (1) LU91214B1 (enExample)
MC (1) MC200083A1 (enExample)
ME (4) ME01670B (enExample)
MX (3) MXPA06004124A (enExample)
MY (1) MY142095A (enExample)
NL (2) NL1029151C2 (enExample)
NO (7) NO334337B1 (enExample)
NZ (3) NZ551668A (enExample)
PE (3) PE20081649A1 (enExample)
PL (6) PL1763368T5 (enExample)
PT (4) PT2292267E (enExample)
RS (4) RS53529B1 (enExample)
RU (4) RU2373935C2 (enExample)
SI (5) SI2292267T1 (enExample)
TW (1) TWI404530B (enExample)
UA (6) UA89185C2 (enExample)
UY (1) UY28933A1 (enExample)
WO (3) WO2005115467A1 (enExample)
ZA (6) ZA200600261B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
NZ545443A (en) * 2003-07-29 2010-04-30 Boehringer Ingelheim Int Combination of an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane and a steroid and its use to treat respiratory disorders by inhalation
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
RU2385156C2 (ru) * 2004-05-31 2010-03-27 Лабораториос Альмираль С.А. Комбинации, содержащие антимускариновые средства и кортикостероиды
WO2006085689A1 (ja) * 2005-02-10 2006-08-17 Oncolys Biopharma, Inc. テロメライシン併用抗癌剤
PL1971369T3 (pl) * 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
WO2007096782A2 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
PT2359826E (pt) * 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
MX2009000475A (es) 2006-07-19 2009-07-10 Astrazeneca Ab Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
KR20150038750A (ko) * 2007-02-21 2015-04-08 알미랄, 에스.에이. 신규 방법
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN103463084A (zh) * 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
PT2297106E (pt) 2008-05-27 2014-09-29 Astrazeneca Ab Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EA024922B1 (ru) 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013031493B1 (pt) 2011-06-10 2022-04-19 Chiesi Farmaceutici S.P.A Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
HUE069624T2 (hu) * 2012-01-25 2025-03-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
US9156833B2 (en) 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
SG10201704032RA (en) 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
US10711334B2 (en) * 2013-10-09 2020-07-14 Mirus Llc Metal alloy for medical devices
BR112016010416B1 (pt) 2013-11-15 2021-10-05 Performance Polyamides, Sas Composição de poliamida, e componente de metal
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX384539B (es) * 2016-01-08 2025-03-14 Theron Pharmaceuticals Inc Composiciones de inhalador de polvo seco de derivados de 7-azoniabiciclo[2.2.1]heptano
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2018211530A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
AU2022350660A1 (en) * 2021-09-23 2024-04-11 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) * 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) * 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
JP2924924B2 (ja) 1992-12-18 1999-07-26 シェリング・コーポレーション 粉末薬物のための吸入器
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
PL182198B1 (en) 1995-06-21 2001-11-30 Asta Medica Ag Pharmaceutic powder holding container with integrated measuring device and powdered
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
AU2001239550A1 (en) * 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002000241A2 (en) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
SI1353919T1 (sl) * 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
WO2002096423A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
CA2487399A1 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
EA200500173A1 (ru) * 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
CA2506949A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
EP1610788A1 (en) * 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PT1610787E (pt) * 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
PT1651270E (pt) * 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005013994A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2550848C (en) * 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
US20110021477A1 (en) 2011-01-27
CN101018566A (zh) 2007-08-15
UY28933A1 (es) 2005-08-31
EP2002845A3 (en) 2009-02-25
US20100056486A1 (en) 2010-03-04
CY1110798T1 (el) 2015-06-10
EP1763369A1 (en) 2007-03-21
EP1763368B1 (en) 2009-03-11
RU2404771C3 (ru) 2018-03-12
ES2318498T3 (es) 2009-05-01
IL179687A0 (en) 2007-05-15
DK1763369T3 (da) 2009-03-16
US20140094442A1 (en) 2014-04-03
RU2006147250A (ru) 2008-07-20
US20150202213A1 (en) 2015-07-23
MY142095A (en) 2010-09-15
US20200009117A1 (en) 2020-01-09
SI2292267T1 (sl) 2014-11-28
JP4928258B2 (ja) 2012-05-09
PL2292267T3 (pl) 2015-03-31
ZA200600261B (en) 2007-04-25
BRPI0511656A (pt) 2008-01-02
NL1029151C2 (nl) 2006-06-22
KR20070024556A (ko) 2007-03-02
US20100048616A1 (en) 2010-02-25
BRPI0511662B8 (pt) 2021-05-25
NO20065479L (no) 2006-12-22
PL1763369T3 (pl) 2009-06-30
ZA200609985B (en) 2008-09-25
TWI404530B (zh) 2013-08-11
NO20065478L (no) 2006-12-28
PL1765404T3 (pl) 2009-06-30
ES2348680T3 (es) 2010-12-10
HK1095757A1 (en) 2007-05-18
IE20050366A1 (en) 2005-11-30
EP2138188A1 (en) 2009-12-30
CA2533061A1 (en) 2005-12-08
AU2005247108B2 (en) 2008-09-11
DE602005011803D1 (de) 2009-01-29
US20120088743A1 (en) 2012-04-12
JP2008500986A (ja) 2008-01-17
EP2774623B1 (en) 2015-04-08
BRPI0511667A (pt) 2008-01-02
NO334337B1 (no) 2014-02-10
US20170049756A1 (en) 2017-02-23
RU2465902C2 (ru) 2012-11-10
RU2006142331A (ru) 2008-06-20
EP2002844A3 (en) 2009-03-04
ES2322280T5 (es) 2013-12-03
NZ544539A (en) 2007-09-28
US20080045565A1 (en) 2008-02-21
UA89185C2 (ru) 2010-01-11
WO2005115462A1 (en) 2005-12-08
US20180200234A1 (en) 2018-07-19
DE602005013220D1 (de) 2009-04-23
CL2011000607A1 (es) 2011-08-19
US20050267135A1 (en) 2005-12-01
TW200608971A (en) 2006-03-16
NO20065482L (no) 2006-12-22
CA2568566A1 (en) 2005-12-08
EP2292267B1 (en) 2014-07-23
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
JP4966192B2 (ja) 2012-07-04
PE20081650A1 (es) 2008-12-06
SI1763368T2 (sl) 2013-12-31
JP5538485B2 (ja) 2014-07-02
PE20060292A1 (es) 2006-04-14
US20100048615A1 (en) 2010-02-25
BRPI0511662B1 (pt) 2019-02-19
EP2002843A3 (en) 2009-04-08
ATE474600T1 (de) 2010-08-15
US20070167489A1 (en) 2007-07-19
MXPA06004124A (es) 2006-06-27
US20140148420A1 (en) 2014-05-29
EP2292267A3 (en) 2011-06-15
HRP20090215T4 (hr) 2013-12-20
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
AU2005247103A1 (en) 2005-12-08
EP2774622B1 (en) 2015-03-11
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
IL179689A (en) 2012-02-29
ES2505329T3 (es) 2014-10-09
JP2008500990A (ja) 2008-01-17
KR101174677B1 (ko) 2012-08-17
EP1891973B1 (en) 2010-07-21
UA86976C2 (ru) 2009-06-10
FR15C0017I2 (fr) 2015-11-13
RU2373935C2 (ru) 2009-11-27
GR20050100269A (el) 2005-12-31
WO2005115466A1 (en) 2005-12-08
ZA200609986B (en) 2007-11-28
PT1891973E (pt) 2010-09-27
ECSP067037A (es) 2006-12-29
ES2322280T3 (es) 2009-06-18
IL179689A0 (en) 2007-05-15
FR2870744A1 (fr) 2005-12-02
AU2005247108A1 (en) 2005-12-08
CY1108885T1 (el) 2014-07-02
US20060154934A1 (en) 2006-07-13
HUP0600139A2 (en) 2007-06-28
SI1763369T1 (sl) 2009-06-30
DK1891973T3 (da) 2010-10-18
ES2257152A1 (es) 2006-07-16
EP2292267A2 (en) 2011-03-09
US20120059031A1 (en) 2012-03-08
SI1891973T1 (sl) 2010-11-30
CN1960762A (zh) 2007-05-09
PT2292267E (pt) 2014-10-15
EP1891973A1 (en) 2008-02-27
US20110021476A1 (en) 2011-01-27
EP2002844A2 (en) 2008-12-17
DK2292267T3 (da) 2014-09-15
EP1763369B1 (en) 2008-12-17
US20130035319A1 (en) 2013-02-07
EP2774622A1 (en) 2014-09-10
ES2348558T3 (es) 2010-12-09
US20080146603A1 (en) 2008-06-19
CY1109139T1 (el) 2014-07-02
ME01680B (me) 2010-08-31
PL1763368T3 (pl) 2009-08-31
CN1972716A (zh) 2007-05-30
EP2210613A1 (en) 2010-07-28
JP2008500987A (ja) 2008-01-17
CY2015006I2 (el) 2016-06-22
DK1765404T3 (da) 2009-03-16
JP2012184272A (ja) 2012-09-27
EP1761280A1 (en) 2007-03-14
NO20065476L (no) 2006-12-28
US20080051378A1 (en) 2008-02-28
UA89183C2 (ru) 2010-01-11
MXPA06013847A (es) 2007-03-01
US20090099148A1 (en) 2009-04-16
ME01670B (me) 2010-06-30
DK1763368T4 (da) 2013-11-04
EP2002844B1 (en) 2010-12-29
ECSP067038A (es) 2006-12-29
AU2005247103B2 (en) 2010-10-28
IL179684A0 (en) 2007-05-15
US20130310354A1 (en) 2013-11-21
US20070232637A1 (en) 2007-10-04
KR101256417B1 (ko) 2013-04-22
RS50787B2 (sr) 2018-02-28
CY2015006I1 (el) 2016-06-22
CN1960761A (zh) 2007-05-09
CH696962A5 (fr) 2008-02-29
KR20070018105A (ko) 2007-02-13
GB0526502D0 (en) 2006-02-08
US20160038470A1 (en) 2016-02-11
SI1763368T1 (sl) 2009-08-31
HRP20100489T1 (hr) 2010-10-31
ECSP067036A (es) 2006-12-29
RU2385721C2 (ru) 2010-04-10
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
CN1960760A (zh) 2007-05-09
US20050267078A1 (en) 2005-12-01
LTC1763368I2 (lt) 2016-12-27
IL179684A (en) 2011-11-30
NL300720I1 (enExample) 2016-01-07
CN102755321B (zh) 2015-07-15
JP2006527183A (ja) 2006-11-30
DE602005022497D1 (de) 2010-09-02
US20060205702A1 (en) 2006-09-14
CA2568566C (en) 2012-12-18
CA2533061C (en) 2008-07-08
HRP20090215T1 (en) 2009-05-31
UA89182C2 (ru) 2010-01-11
HRP20090107T3 (en) 2009-03-31
AR049066A1 (es) 2006-06-21
US20120309726A1 (en) 2012-12-06
ECSP067035A (es) 2006-12-29
ES2293849B2 (es) 2009-04-16
BRPI0511669A (pt) 2008-01-02
RU2006147268A (ru) 2008-07-20
JP5032984B2 (ja) 2012-09-26
KR20130027586A (ko) 2013-03-15
JP5049120B2 (ja) 2012-10-17
GB2419819B (en) 2007-02-21
JP5133054B2 (ja) 2013-01-30
MXPA06013848A (es) 2007-03-01
JP2008500988A (ja) 2008-01-17
PT1763369E (pt) 2009-02-26
HUS1500011I1 (hu) 2018-09-28
ES2293849A1 (es) 2008-03-16
WO2005115467A1 (en) 2005-12-08
MC200083A1 (fr) 2005-12-07
IL179687A (en) 2011-11-30
NO2015007I2 (no) 2015-12-21
PT1763368E (pt) 2009-05-14
RU2010129940A (ru) 2012-01-27
RS53529B1 (sr) 2015-02-27
CY1109938T1 (el) 2014-09-10
PL1891973T3 (pl) 2010-11-30
US20150306079A1 (en) 2015-10-29
EP1765404A1 (en) 2007-03-28
EP1765404B1 (en) 2008-12-31
CN102085373A (zh) 2011-06-08
ZA200609989B (en) 2007-11-28
ECSP067033A (es) 2006-12-29
CN1960759A (zh) 2007-05-09
WO2005115466A8 (en) 2007-01-04
US20060189651A1 (en) 2006-08-24
CY1115669T1 (el) 2017-01-25
NZ551667A (en) 2010-07-30
RU2404771C2 (ru) 2010-11-27
GB2419819A (en) 2006-05-10
HRP20140864T1 (hr) 2014-12-05
US20150080359A1 (en) 2015-03-19
ATE417627T1 (de) 2009-01-15
US20110021478A1 (en) 2011-01-27
HUP0600139A3 (en) 2010-12-28
NO20065477L (no) 2006-12-22
US20090093503A1 (en) 2009-04-09
BRPI0511662A (pt) 2008-01-02
US20120040943A1 (en) 2012-02-16
US20130252928A1 (en) 2013-09-26
EP2002843A2 (en) 2008-12-17
EP1763368A1 (en) 2007-03-21
NO338621B1 (no) 2016-09-19
EP2319538A3 (en) 2011-06-15
JP2008500989A (ja) 2008-01-17
US20120302532A1 (en) 2012-11-29
JP5107701B2 (ja) 2012-12-26
EP2319538A2 (en) 2011-05-11
ITMI20051021A1 (it) 2005-12-01
FR2870744B1 (fr) 2006-12-08
BRPI0511660A (pt) 2008-01-02
NL300720I2 (enExample) 2016-01-07
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
EP2002845A2 (en) 2008-12-17
BRPI0511666A (pt) 2008-01-02
CA2569077A1 (en) 2005-12-08
HK1090306A1 (en) 2006-12-22
FR15C0017I1 (enExample) 2015-03-04
EP2774623A1 (en) 2014-09-10
SI21784A (sl) 2005-12-31
CN1960759B (zh) 2011-07-13
JP2012012407A (ja) 2012-01-19
PL1763368T5 (pl) 2014-01-31
NL1029151A1 (nl) 2005-12-05
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
PL379660A1 (pl) 2006-11-13
CN102755321A (zh) 2012-10-31
AU2005247107A1 (en) 2005-12-08
CY1108902T1 (el) 2014-07-02
US20090176751A1 (en) 2009-07-09
BE1016608A5 (fr) 2007-02-06
US20090111785A1 (en) 2009-04-30
ZA200609987B (en) 2007-12-27
DK1763368T3 (da) 2009-05-04
CA2569077C (en) 2012-12-18
ES2257152B1 (es) 2007-07-01
HK1125573A1 (en) 2009-08-14
HK1198120A1 (en) 2015-03-13
PE20081649A1 (es) 2008-11-28
GR1006045B (el) 2008-09-08
AU2005247107B2 (en) 2010-10-28
EP1763368B2 (en) 2013-08-21
RS51386B (sr) 2011-02-28
NO20065483L (no) 2006-12-22
ZA200609990B (en) 2007-12-27
ME02779B (me) 2010-06-30
ECSP067034A (es) 2006-12-29

Similar Documents

Publication Publication Date Title
ME02134B (me) Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergične agoniste
ATE426614T1 (de) Pyy-agonisten und anwendungen davon
CY2017027I2 (el) Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
ATE413105T1 (de) Eiskonfekt und haltemittel
EP1771786A4 (en) SAMPLE PROCESSING SIMULTANEOUS
DE102004032572A8 (de) Verbindungsanordnung und Kontaktstift
DE602006020061D1 (de) Mucin-glycoprotein und anwendung davon
PL1597967T3 (pl) Kompozycje zawierające cyklopropeny i środki kompleksujące metale
ATE538093T1 (de) Substituierte 2-carbonylamino-6- piperidinaminopyridine und substituierte 1- carbonylamino-3-piperidinaminobenzole als 5-ht1f- agonisten
PL1926477T3 (pl) Kompozycja zawierająca NLPZ oraz paracetamol
ATE449633T1 (de) Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
FI20041057L (fi) Pelkistysainekoostumus
EP1850848A4 (en) SULFONAMIDE TETRACYCLIC COMPOUNDS AND METHODS OF USING THE SAME
ATE432703T1 (de) Substituierte phenylacetamide und ihre anwendung als protease inhibitoren
DE602005017283D1 (de) Ausgewählte kondensierte heterocyclen und deren anwendung
IT1326908B1 (it) Dispositivo e procedimento di bobinatura di
DE602005008397D1 (de) Gehäusestruktur aus pressholz
DE602005005656D1 (de) Gehäusestruktur aus pressholz
DE602006018325D1 (de) Esterasegen und anwendung davon
SE0400613D0 (sv) New compounds and use thereof
ATE547408T1 (de) Heterocyclische amidverbindung und anwendung davon
ITPZ20040001U1 (it) Digita e vedi
SE0403161D0 (sv) Ny användning av glucosine
ITPG20050004A1 (it) Tinti e maltini di bacco

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1763368

Country of ref document: EP

EEFA Change of the company name